Single Blinded First CMC Osteoarthritis Treatment (NCT03196310) | Clinical Trial Compass
TerminatedNot Applicable
Single Blinded First CMC Osteoarthritis Treatment
Stopped: Due to lack of enrollment, challenging follow-up, and lack of funding.
United States74 participantsStarted 2018-09-01
Plain-language summary
Single blinded PRP vs. Corticosteroid vs. Placebo (normal saline) intra-articular injection for basal joint arthritis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Stage 1-3 osteoarthritis of the basal joint
Exclusion Criteria:
* Patients with Stage 4 1st carpometacarpal joint arthritis as described by Eaton
* Patients who have received a corticosteroid injection in the last year to the 1st CMC joint on the proposed study side
* Patients who have scaphotriquetral, radioscaphoid, or scaphotrapezial osteoarthritis
* Patients who have concurrent DeQuervain's tenosynovitis or intersection syndrome or have been treated for either of these in the last 3 months
* Patients undergoing evaluation of cervical radiculopathy
* Patients with fibromyalgia or inflammatory rheumatic disease
* Patients with Pressier disease, Kienbock's, or avascular necrosis of the scaphoid
* Patients with any history of primary or secondary bone tumor
* Patients that are pregnant or terminally ill